Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23703827 | 0.91 | EPHX2 (0.44) | HIF1ATSHREPHX2MAPTFAAH | |
| SCHEMBL2552628 | 0.91 | EPHX2 (0.44) | HIF1ATSHREPHX2MAPTFAAH | |
| SCHEMBL2332433 | 0.86 | — | — | |
| SCHEMBL28903229 | 0.80 | NOS3 (0.38) | EPHX2NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL21815374 | 0.80 | NOS3 (0.38) | TSHREPHX2NOS3NOS1NOS2 | |
| SCHEMBL8376071 | 0.78 | EPHX2 (0.40) | TSHREPHX2NOS3NOS1NOS2 | |
| SCHEMBL30957285 | 0.78 | EPHX2 (0.40) | TSHREPHX2NOS3NOS1NOS2 | |
| SCHEMBL15103300 | 0.78 | EPHX2 (0.40) | TSHREPHX2NOS3NOS1NOS2 | |
| SCHEMBL16098323 | 0.77 | HIF1A (0.35) | HIF1ATSHRMAPT | |
| SCHEMBL17117118 | 0.77 | EPHX2 (0.35) | HIF1ATSHREPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| EP-3131586-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3129064-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015143004-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015134464-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838909-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158644-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-5130312-A | Gastrointestinal motility stimulators | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-07-14 | — | — | US | disclosed |